Revance Therapeutics

$24.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.36 (+1.50%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell RVNC and other stocks, options, and ETFs commission-free!

About RVNC

Revance Therapeutics, Inc. Common Stock, also called Revance Therapeutics, is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA. The listed name for RVNC is Revance Therapeutics, Inc. Common Stock.

CEO

Mark J. Foley

Employees

193

Headquarters

Newark, California

Founded

1999

Market Cap

1.62B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

453.89K

High Today

$24.48

Low Today

$23.84

Open Price

$24.26

Volume

248.89K

52 Week High

$34.62

52 Week Low

$11.78

Collections

Analyst Ratings

91%

of 11 ratings

Buy

91%

Hold

Sell

RVNC Earnings

-$1.34

-$0.89

-$0.45

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 24, After Hours